Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1626-1631
Published online before print April 6, 2006, doi: 10.1161/01.ATV.0000220374.00602.a2
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
26/7/1626    most recent
01.ATV.0000220374.00602.a2v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, S. P.
Right arrow Articles by Parise, L. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S. P.
Right arrow Articles by Parise, L. V.
Related Collections
Right arrow Coagulation
Right arrow Platelets
Right arrow Other Vascular biology
Right arrowRelated Article
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1626.)
© 2006 American Heart Association, Inc.


Thrombosis

Biologically Active CD40 Ligand Is Elevated in Sickle Cell Anemia

Potential Role for Platelet-Mediated Inflammation

Sheritha P. Lee; Kenneth I. Ataga; Eugene P. Orringer; David R. Phillips; Leslie V. Parise

From the Departments of Pharmacology (S.P.L., L.V.P.) and Medicine (K.I.A., E.P.O.), the University of North Carolina at Chapel Hill; and Millennium Pharmaceuticals (D.R.P.), South San Francisco, Calif. D.R.P.’s current address: Portola Pharmaceuticals, Inc, 270 E Grand, Ste 22, South San Francisco, CA 94080.

Correspondence to Dr Leslie V. Parise, Department of Pharmacology, University of North Carolina, CB#7365, Chapel Hill, NC 27599-7365. E-mail parise{at}med.unc.edu

Objective— After activation, platelets expose CD40 ligand (CD40L) on their surface, then subsequently release the inflammatory mediator as a soluble fragment (sCD40L). Because sickle cell anemia (SCA) is noted for both platelet activation and chronic inflammation, we asked whether platelet-released CD40L potentially plays a role in SCA.

Methods and Results— ELISAs demonstrate that SCA patient plasma contains 30-fold more sCD40L than control plasma. Correspondingly, platelets from these patients contain less than half the CD40L found in control platelets. Platelets from patients in painful crises are further depleted of CD40L, with even higher plasma levels, suggesting a correlation to the patient’s clinical state. In addition, elevated sCD40L correlates with increased tissue factor in SCA plasma. Blockage of the CD40L receptor CD40 reduces SCA plasma-induced production of tissue factor and endothelial intercellular adhesion molecule-1 (ICAM-1). Finally, sCD40L activity in SCA plasma is confirmed by its induction of B-cell proliferation.

Conclusions— Platelet-derived sCD40L is elevated in SCA, further elevated in crises, and biologically active. The participation of sCD40L in SCA plasma-induced production of B cells, tissue factor, and ICAM-1 suggests that CD40L may contribute to the chronic inflammation and increased thrombotic activity known to occur in SCA.

CD40L is elevated in plasma but depleted from platelets in sickle cell anemia (SCA). These differences are exaggerated during painful crises. CD40L is implicated in SCA plasma-induced production of tissue factor, ICAM-1, and B cells, suggesting that platelet-derived CD40L contributes to inflammation and coagulation in SCA.


Key Words: CD40L • sickle cell anemia • platelets • inflammation • coagulation


Related Article:

Vasoocclusion in Sickle Cell Anemia: Are Platelets Really Involved?
Joel S. Bennett
Arterioscler Thromb Vasc Biol 2006 26: 1415-1416. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
N. Li
Platelet-lymphocyte cross-talk
J. Leukoc. Biol., May 1, 2008; 83(5): 1069 - 1078.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
M. T. Gladwin and G. J. Kato
Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!
Haematologica, January 1, 2008; 93(1): 1 - 3.
[Full Text] [PDF]


Home page
haematolHome page
K. I. Ataga, C. G. Moore, C. A. Hillery, S. Jones, H. C. Whinna, D. Strayhorn, C. Sohier, A. Hinderliter, L. V. Parise, and E. P. Orringer
Coagulation activation and inflammation in sickle cell disease-associated pulmonary hypertension
Haematologica, January 1, 2008; 93(1): 20 - 26.
[Abstract] [Full Text] [PDF]


Home page
Circ. Res.Home page
P. von Hundelshausen and C. Weber
Platelets as Immune Cells: Bridging Inflammation and Cardiovascular Disease
Circ. Res., January 5, 2007; 100(1): 27 - 40.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
M. J. Telen
Role of Adhesion Molecules and Vascular Endothelium in the Pathogenesis of Sickle Cell Disease
Hematology, January 1, 2007; 2007(1): 84 - 90.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
J. S. Bennett
Vasoocclusion in sickle cell anemia: are platelets really involved?
Arterioscler Thromb Vasc Biol, July 1, 2006; 26(7): 1415 - 1416.
[Full Text] [PDF]